Sterile Production According To The New EU GMP Annex 1: A Focus On Capping - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sterile Production According To The New EU GMP Annex 1: A Focus On Capping
Regulations governing sterile manufacture of pharmaceuticals have been significantly revised since their introduction. The recent amendment to Annex 1 has seen the most controversial changes relating to the capping of vials. Pharmaceutical Inspection Cooperation Scheme has provided an interpretation of the guidelines and has published a report that offers advice on how to comply with the new recommendations. Capping is the particular focus of this article.


Pharmaceutical Technology Europe
Volume 22, Issue 8


GETTY IMAGES/CHRISTINE BALDERAS
Regulations governing the manufacture of sterile pharmaceuticals in the US and Europe have been significantly revised over the past few years. The first milestone was set by the FDA's Guidance for Industry Sterile Drug Products Produced by Aseptic Processing" — "Aseptic Guide in 2004. In 2008, four parts of the EU GMP Guide Annex 1 Manufacture of Sterile Medicinal Products were extensively revised. Annex 1 became fully effective on 3 January 2010.

Another important document that often receives little attention is the PIC/S (Pharmaceutical Inspection Cooperation Scheme; http://www.picscheme.org/) recommendation PI 0075 "Validation of Aseptic Processes". Primarily aimed at pharmaceutical inspectors, this document also aids the pharmaceutical user in the interpretation and implementation of the new Annex 1 standards. In the course of the Annex 1 revision, the PIC/S document underwent several revisions and now corresponds with the current guideline.

The revised version of EU GMP Guide Annex 1 Manufacture of Sterile Medicinal Products

The revised version of Annex 1 primarily applies to four partial aspects:
  • Clean room and clean air device classification
  • Process simulation / media fill
  • Bioburden monitoring
  • Finishing of sterile products

Clean room and clean air device classification has been developed to be harmonised with the standard EN ISO 14644. For Process simulation / media fill the requirements were harmonised with the standards of the FDA Aseptic Guide. These standards were also adopted in the PIC/S document PI 007-5. The specifications for Finishing of sterile products generated a much higher need for text interpretation. The new specifications, particularly for capping vials, have also caused uncertainty for inspectors in the pharmaceutical industry.

To eliminate this uncertainty, the PIC/S published another document in January 2010, introducing the changes in Annex 1 and interpreting the new specifications. The document PIC/S recommendation PI 0322 GMP Annex 1 revision 2008, interpretation of most important changes for the manufacture of sterile medicinal products was prepared under the leadership of Swiss inspectors from Swissmedic.

The most controversial changes made to Annex 1 were found in the section for Finishing of sterile products and related to the capping of vials. Some statements in Annex 1 concerning this matter were clarified in the PIC/S document and are presented here in more detail. The PIC/S interpretations are supplemented with two case studies from pharmaceutical companies.


The author says...
Interpretations

1. "Grade A air supply" — definition, qualification and monitoring requirements (Annex 1 Section 120)

"Grade A air supply" was listed again in Annex 1 but not defined. PIC/S clearly explains the need to discern between Grade A air supply and Grade A area and defines the terms as follows:

"Grade A air supply is specifically used to describe a supply of air which is HEPA filtered, and at the point of supply meets, when tested, the non-viable particulate requirements of a Grade A area."

It is important to differentiate between the terms Grade A air supply and Grade A area. According to PIC/S, a Grade A air supply should be qualified and monitored; the qualification is to be performed in an "at rest" state. For the capping machine the "at rest" state is achieved when the air intake is switched on, the machine is operating (but without vials being fed and needing to be capped), and there is no user operation. For the transport tunnel the "at-rest" state is reached when the air intake and the conveyer are switched on and there is no user operation.

The requirements for nonliving particles are to meet Grade A area requirements. The sample is to be taken from beneath the air outlet and smoke studies are to be performed. A unidirectional air flow is not required. However, an efficient protection for the vial is to be proven, particularly an absence of ambient air entering. Rational air speed limitations should exist. Companies must determine monitoring requirements for nonliving particles and microbiological contaminations in line with a risk analysis.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here